Clinical Trial Search

Phase 3 N=870 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Melanoma

Primary: Percentage of Participants With Relapse-free Survival (RFS) Events — 163; 247; 3; 1 Participants

Novartis Pharmaceuticals Results Sep 2018 23.0% serious AE View details

Phase 3 N=1,326 Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1

Infertility

Primary: Ongoing Pregnancy Rate — 30.7; 31.6 Percentage of subjects

Ferring Pharmaceuticals Results Sep 2018 2.0% serious AE View details

Phase 3 N=215 Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

Chronic Liver Disease · Thrombocytopenia

Primary: Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7…

Shionogi Results Sep 2018 6.5% serious AE View details

Phase 3 N=564 Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Hyperhidrosis

Primary: Long-term Safety Assessed Through Adverse Events and Local Skin Reactions — 148; 153; 28; 120 Adverse Events and Local Skin Reactions

Journey Medical Corporation Results Sep 2018 1.3% serious AE View details

Phase 3 N=954 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

Primary: Overall Survival (OS) — 13.6; 12.3 months

Eisai Limited Results Sep 2018 37.6% serious AE View details

Phase 3 N=80 A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II) — -18.39; -92.22; -44.75; -96.72 Percent change in anti-fXa activity — p=<0.0001

Portola Pharmaceuticals Results Sep 2018 0.0% serious AE View details

Phase 3 N=14 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

Primary: Percent Change From Baseline in OV/BV at Week 48 — -54.18 percentage change of unmineralized bone — p=< 0.0001

Kyowa Kirin, Inc. Results Sep 2018 28.6% serious AE View details

Phase 3 N=513 Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2

Infertility

Primary: Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation…

Ferring Pharmaceuticals Results Sep 2018 1.3% serious AE View details

Phase 3 N=34 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Primary Sclerosing Cholangitis

Primary: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 — 10; 6 Participants

Stanford University Results Sep 2018 2.9% serious AE View details

Phase 3 N=115 Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

Urinary Tract Infection (UTI) · Complicated Urinary Tract Infection · Pyelonephritis

Primary: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) — 80.7 Percentage of participants

Merck Sharp & Dohme LLC Results Sep 2018 11.4% serious AE View details

Phase 3 N=30 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma

Intraocular Retinoblastoma

Primary: Group D Eyes - Treatment Failure Within One Year — 0.52 Probability of treatment failure

Children's Oncology Group Results Sep 2018 0.0% serious AE View details

Phase 3 N=726 Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Advanced Breast Cancer

Primary: Progression Free Survival (PFS) Per Investigator Assessment — 20.5; 12.8 Months — p=0.00000041

Novartis Pharmaceuticals Results Sep 2018 31.8% serious AE View details

Phase 3 N=240 Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies — 63; 53 Participants

GlaxoSmithKline Results Sep 2018 6.7% serious AE View details

Phase 3 N=220 Self-Administered Lidocaine Gel for Pain Management With IUD Insertion

IUD Insertion

Primary: (IUD Insertion): Pain Perceived by Visual Analogue Scale (0-100 mm) Immediately Following Procedure Completion — 65; 59 score on a scale

Stanford University Results Sep 2018 0.0% serious AE View details

Phase 3 N=650 A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

Primary: Mean Change From Baseline in HbA1c at Week 24 — -1.67; -1.54 % HbA1c — p=0.118

AstraZeneca Results Sep 2018 5.1% serious AE View details